CONCERT PHARMACEUTICALS, INC. 8-K SEC Filings

THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of March 6, 2023 (this “Agreement”), is entered into by and between Sun Pharmaceutical Holdings USA, Inc., a Delaware corporation (“SPH”), Sun Pharmaceutical Industries Ltd., an entity org...

THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of January 19, 2023, by and among: SUN PHARMACEUTICAL INDUSTRIES LTD., an entity organized under the laws of India (“Parent”); FOLIAGE MERGER SUB, INC., a D...

Lexington, MA (November 7, 2022) -- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2022.

On August 16, 2022 and August 19, 2022, Concert Pharmaceuticals, Inc. (the “Company”) received an aggregate of $20.9 million upon exercise of the remaining tranche 1 warrants to purchase 4,144 shares of Series X1 Preferred Stock issued t...

Conference Call Scheduled Today at 8:30 a.m. ET; Online Registration Required to Access Dial in and PIN for Live Call to Ask Questions

At the 2022 Annual Meeting of Stockholders of Concert Pharmaceuticals, Inc. (the “Company”) held on June 9, 2022, the Company’s stockholders voted as follows:

Introductory. Concert Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 10,000,000 shares of its common stock, p...

Exhibit 99.1 Creating New Possibilities for Patients to Live Their Lives May 2022 © 2022 Concert Pharmaceuticals, Inc. All Rights Reserved.

On May 12, 2021, the Patent Trial and Appeal Board (the “PTAB”) of the U.S. Patent and Trademark Office instituted a post grant review of U.S. Patent No. 10,561,659 (the “’659 Patent”) owned by Concert Pharmaceuticals, Inc. (the “Company...

Lexington, MA (May 5, 2022) -- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2022.

Lexington, MA (March 3, 2022) -- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the year ended December 31, 2021.

On January 31, 2022, Ronald W. Barrett notified Concert Pharmaceuticals, Inc. (the “Company”) that he will not stand for re-election at the Company’s 2022 Annual Meeting of Stockholders. Dr. Barrett’s decision to not stand for re-electio...

CTP-543 THRIVE-AA1 Phase 3 Trial in Patients with Moderate to Severe Alopecia Areata Fully Enrolled with Topline Data Expected Second Quarter of 2022

This Securities Purchase Agreement (this “Agreement”) is dated as of November 3, 2021, between Concert Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, incl...

Lexington, MA (August 5, 2021) -- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2021.

At the 2021 Annual Meeting of Stockholders of Concert Pharmaceuticals, Inc. (the “Company”) held on June 10, 2021, the Company’s stockholders voted as follows:

Exhibit 10.1 AMENDMENT TO ASSET PURCHASE AGREEMENT This AMENDMENT TO ASSET PURCHASE AGREEMENT (this “Amendment”), dated as of May 17, 2021, to that certain Asset Purchase Agreement (as may be further amended or modified from time to time...

On May 12, 2021, the Patent Trial and Appeal Board (the “PTAB”) of the U.S. Patent and Trademark Office instituted a post grant review (“PGR”) of U.S. Patent No. 10,561,659 (the “’659 Patent”) owned by Concert Pharmaceuticals, Inc. (the ...

Lexington, MA (May 4, 2021) -- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2021.

CTP-543 Long-Term Data Presented at EADV Show Hair Regrowth was Maintained or Improved in Patients with Alopecia Areata, Expanding Previous Phase 2 Results